SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Incyte Corp – ‘8-K’ for 3/25/20

On:  Thursday, 3/26/20, at 4:08pm ET   ·   For:  3/25/20   ·   Accession #:  1104659-20-38786   ·   File #:  1-12400

Previous ‘8-K’:  ‘8-K’ on / for 2/13/20   ·   Next:  ‘8-K’ on 4/20/20 for 4/14/20   ·   Latest:  ‘8-K’ on / for 2/13/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/26/20  Incyte Corp                       8-K:5       3/25/20   10:186K                                   Toppan Merrill/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     30K 
 7: R1          Cover                                               HTML     47K 
 5: XML         IDEA XML File -- Filing Summary                      XML     11K 
10: XML         XBRL Instance -- tm2013772d1_8k_htm                  XML     14K 
 6: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.LAB  XBRL Labels -- incy-20200325_lab                     XML     96K 
 4: EX-101.PRE  XBRL Presentations -- incy-20200325_pre              XML     64K 
 2: EX-101.SCH  XBRL Schema -- incy-20200325                         XSD     12K 
 8: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
 9: ZIP         XBRL Zipped Folder -- 0001104659-20-038786-xbrl      Zip     11K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0000879169  i false 0000879169 2020-03-24 2020-03-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):   i March 25, 2020

 

 i INCYTE CORPORATION

(Exact name of registrant as specified in its charter)

 

 i Delaware
(State or Other Jurisdiction of
Incorporation)
   i 001-12400
(Commission File Number)
   i 94-3136539
(I.R.S. Employer
Identification No.)

 

 i 1801 Augustine Cut-Off  
 i Wilmington,  i DE  i 19803
(Address of principal executive offices) (Zip Code)

 

( i 302)  i 498-6700

(Registrant’s telephone number,
including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

 i ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 i ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 i ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 i ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)    Name of each exchange on which registered
 i Common Stock, $.001 par value per share    i INCY    i The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

 

Emerging growth company    i ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 C: 

 

 

  

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Election of Directors

 

Effective March 25, 2020, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to ten and elected Katherine A. High, M.D. a member of the Board of Directors of the Company.

 

Dr. High, age 68, served as President of Spark Therapeutics, Inc., a gene therapy company, from September 2014 until February 2020 and served as Head of Research and Development of Spark from September 2017 until February 2020. From September 2014 through September 2017, Dr. High served as Chief Scientific Officer of Spark. Prior to serving as President of Spark, Dr. High provided advice to Spark and subsequently served as an independent consultant to Spark from December 2013 to September 2014. From July 1999 through September 2014, Dr. High was a Professor at the Perelman School of Medicine at the University of Pennsylvania. From March 2003 through September 2014, Dr. High was an Investigator of the Howard Hughes Medical Institute. Dr. High served as the Director of the Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia from September 2004 to April 2014. Dr. High is also a member of the board of directors of CRISPR Therapeutics AG and served on the board of directors of Spark from September 2014 until its acquisition in December 2019.

 

There is no arrangement or understanding between Dr. High and any other person pursuant to which she was selected as a director of the Company, and there is no family relationship between Dr. High and any of the Company’s other directors or executive officers. The Company is not aware of any transaction involving Dr. High requiring disclosure under Item 404(a) of Regulation S-K.

 

As a non-employee member of the Board of Directors of the Company, Dr. High will be entitled to receipt of the same cash and equity compensation paid by the Company to each of its non-employee directors, as described in the Company’s proxy statement for its 2019 Annual Meeting of Stockholders filed on March 21, 2019.

 

 C: 
 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 26, 2020

 

  INCYTE CORPORATION
     
  By: /s/ Maria E. Pasquale
    Maria E. Pasquale
    Executive Vice President and
    General Counsel

 

 C: 
 

 

 

 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:3/26/203,  4
For Period end:3/25/20UPLOAD
3/21/19DEF 14A
 List all Filings 
Top
Filing Submission 0001104659-20-038786   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 7:59:32.1am ET